Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTIVE-U Sub-Study C: Vepdegestrant + Samuraciclib in ER+/HER2- Advanced Breast Cancer
NCT06125522Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jan 2024
- Primary completion
- Sep 2026
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 4
01
Overview
A Phase 2 trial of vepdegestrant in breast cancer, sponsored by Pfizer. Started Jan 2024; status: terminated.
02
Drugs
vepdegestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06125522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06125522.